Search
Clobetasol
go.drugbank.com/drugs/DB11750ApprovedInvestigationalWithdrawnClobetasol is under investigation for the treatment of Scleroderma. Clobetasol has been investigated for the prevention of Psoriasis and Cutaneous Atrophy Due to Corticosteroids.
Categories: Corticosteroid Hormone Receptor Agonists, Cytochrome P-450 SubstratesAnisodamine
go.drugbank.com/drugs/DB11785InvestigationalAnisodamine has been investigated for the treatment of Intestinal Diseases.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesMirodenafil
go.drugbank.com/drugs/DB11792InvestigationalMirodenafil has been used in trials studying the treatment and supportive care of Kidney Diseases, Urologic Diseases, Renal Insufficiency, Erectile Dysfunction, and Male Erectile Dysfunction.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesSaracatinib
go.drugbank.com/drugs/DB11805InvestigationalSaracatinib has been investigated for the treatment of Cancer, Osteosarcoma, Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer.
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsCrizotinib
go.drugbank.com/drugs/DB08865ApprovedInvestigationalCrizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic
Categories: Receptor Tyrosine Kinase Inhibitors, P-glycoprotein inhibitorsBrentuximab vedotin
go.drugbank.com/drugs/DB08870ApprovedInvestigationalBrentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsFidaxomicin
go.drugbank.com/drugs/DB08874ApprovedInvestigationalFidaxomicin is a novel macrolide antibiotic used in the treatment of diarrhea caused by Clostridioides (formerly Clostridium) difficile in adult and pediatric patients over the age of 6 months. Fidaxomicin is a naturally-occurring 18-mem...
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP3A InhibitorsGlycerol phenylbutyrate
go.drugbank.com/drugs/DB08909ApprovedInvestigationalGlycerol phenylbutyrate is a nitrogen-binding agent. Chemically, it is a triglyceride in which three molecules of phenylbutyrate are linked to a glycerol backbone. FDA approved on February 1, 2013.
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP2D6 InhibitorsPomalidomide
go.drugbank.com/drugs/DB08910ApprovedInvestigationalPomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesLuliconazole
go.drugbank.com/drugs/DB08933ApprovedInvestigationalLuliconazole is a topical antifungal agent that acts by unknown mechanisms but is postulated to involve altering the synthesis of fungi cell membranes. It was approved by the FDA (USA) in November 2013 and is marketed under the brand nam...
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP2C19 Inhibitors